PLA2R-negative subgroup, n=17 | PLA2R-positive subgroup, n=13 | P value | |
Age (years) | 35.76±12.63 | 30.08±12.86 | 0.24 |
Gender (male/female) | 3/14 | 2/11 | 0.87 |
Positive anti-dsDNA antibody, n (%) | 9 (52.9) | 3 (23.1) | 0.10 |
SLEDAI score | 13.29±4.18 | 10.31±4.38 | 0.07 |
IgG (mg/dL) | 1424.71±731.89 | 1021.75±426.74 | 0.09 |
IgM (mg/dL) | 104.59±68.59 | 124.00±76.04 | 0.49 |
IgA (mg/dL) | 282.29±121.33 | 211.67±110.40 | 0.12 |
C3 (mg/dL) | 39.82±24.16 | 73.08±44.68 | 0.03 |
C4 (mg/dL) | 7.41±7.40 | 16.58±12.19 | 0.02 |
WCC (×109/L) | 3.51±1.56 | 6.56±4.75 | 0.04 |
HB (g/dL)(g/L) | 93.94±22.69 | 114.12±22.56 | 0.02 |
PLT (×109/L) | 140.12±48.75 | 212.62±62.25 | 0.01 |
Urine protein (g/g) | 3.40 (2.30, 4.44) | 2.54 (0.53, 6.64) | 0.62 |
Haematuria | 119.90 (60.90, 287.55) | 57.20 (23.15, 114.35) | 0.79 |
Serum albumin (g/L) | 23.94±7.12 | 26.54±10.39 | 0.45 |
Serum creatinine (μmol/L) | 75.00 (65.00, 104.00) | 61.00 (53.00, 82.00) | 0.94 |
eGFR (mL/min/1.73 m2) | 79.94±30.95 | 103.15±37.21 | 0.07 |
Pathological classification, n (%) | 0.09 | ||
Ⅱ | 0 (0) | 0 (0) | |
Ⅲ/Ⅳ | 9 (52.9) | 3 (23.1) | |
Ⅴ | 4 (23.5) | 8 (61.5) | |
Ⅲ/Ⅳ+Ⅴ | 4 (23.5) | 2 (15.4) | |
Crescent, n (%) | 5 (29.4) | 3 (23.1) | 0.69 |
Glomerular sclerosis, n (%) | 7 (41.2) | 5 (38.5) | 0.88 |
C3 deposition, n (%) | 11 (64.7) | 3 (23.1) | 0.02 |
C4 deposition, n (%) | 9 (52.9) | 3 (23.1) | 0.09 |
C1q deposition, n (%) | 12 (70.6) | 7 (52.8) | 0.60 |
IgM deposition, n (%) | 13 (76.5) | 7 (53.8) | 0.19 |
IgA deposition, n (%) | 14 (82.4) | 4 (30.8) | 0.01 |
IgG deposition, n (%) | 16 (94.1) | 12 (92.3) | 0.84 |
IgG1 deposition | 17 (100) | 12 (92.3) | 0.25 |
IgG2 deposition | 16 (94.1) | 7 (53.8) | 0.01 |
IgG3 deposition | 14 (82.4) | 7 (53.8) | 0.04 |
Multisite deposits under EM (≥2 sites), n (%) | 17 (100) | 13 (100) | |
Subendothelial deposit | 10 (58.8) | 5 (38.5) | 0.27 |
Immunosuppressive treatment, n (%) | 0.67 | ||
Steroids+cyclophosphamide | 4 (23.5) | 1 (7.7) | |
Steroids+mycophenolate mofetil | 4 (23.5) | 3 (23.1) | |
Steroids+ciclosporin/tacrolimus | 4 (23.5) | 4 (30.8) | |
Steroids+others | 5 (29.4) | 5 (38.5) | |
Follow-up (months) | 33.56±12.03 | 34.54±12.21 | 0.57 |
Treatment response, n (%) | 0.59 | ||
CR | 11 (64.7) | 6 (46.2) | |
PR | 4 (23.5) | 5 (41.7) | |
No response | 2 (11.8) | 2 (16.7) | |
Renal outcome events, n (%) | 1 (5.9%) | 0 (0%) | 0.37 |
CR, complete response; dsDNA, double-stranded DNA; eGFR, estimated glomerular filtration rate; EM, electron microscopy; HB, haemoglobin; PLA2R, phospholipase A2 receptor; PLT, platelet; PR, partial response; SLEDAI, Systemic Lupus Erythematous Disease Activity Index; WCC, white cell count.